Literature DB >> 19816865

Association of cystatin C with ischemia in patients with coronary heart disease.

Rajet Deo1, Michael G Shlipak, Joachim H Ix, Sadia Ali, Nelson B Schiller, Mary A Whooley.   

Abstract

BACKGROUND: Elevated concentrations of cystatin C are associated with greater cardiovascular morbidity and mortality. We sought to determine whether elevated concentrations of cystatin C were associated with inducible ischemia in patients with coronary heart disease (CHD).
METHODS: We measured serum cystatin C and performed exercise treadmill testing with stress echocardiography in a cross-sectional study of 899 outpatients with CHD.
RESULTS: Among the 241 participants in the highest quartile of cystatin C (>1.30 mg/L), 38% had inducible ischemia, compared with 13% of those in the lowest quartile of cystatin C < 0.92 mg/L; adjusted odds ratio [OR]: 2.1; 95% confidence interval [CI]: 1.2 to 3.8; p = 0.01). However, this association differed in participants with and without a history of coronary artery bypass graft (CABG), as well as in users and nonusers of beta-blockers and statins (p values for interaction < 0.1). Among participants without a history of CABG, 35% of those in the highest quartile and 9% of those in the lowest quartile of cystatin C had inducible ischemia (adjusted OR: 3.05; 95% CI: 1.3-6.9; p = 0.008). Among participants who were not using beta-blockers, 44% of those in the highest quartile and 7% in the lowest quartile of cystatin C had inducible ischemia (adjusted OR: 5.3; 95% CI: 1.8-15.5; p = 0.002). Among participants who were not using statins, 39% of participants in the highest quartile and 4% of those in the lowest quartile had inducible ischemia (adjusted OR: 10.3; 95% CI: 2.5-43.3; p = 0.001).
CONCLUSIONS: Elevated levels of cystatin C are independently associated with inducible ischemia among outpatients with stable coronary disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816865      PMCID: PMC2818322          DOI: 10.1002/clc.20465

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  25 in total

1.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).

Authors:  James L Januzzi; Christopher P Cannon; Peter M DiBattiste; Sabina Murphy; William Weintraub; Eugene Braunwald
Journal:  Am J Cardiol       Date:  2002-12-01       Impact factor: 2.778

2.  Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting.

Authors:  L Cortigiani; E Picano; C Coletta; F Chiarella; W Mathias; N Gandolfo; M De Alcantara; V Mazzoni; G F Gensini; P Landi
Journal:  Am Heart J       Date:  2001-04       Impact factor: 4.749

Review 3.  Stress echocardiography: current methodology and clinical applications.

Authors:  William F Armstrong; William A Zoghbi
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

4.  Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment.

Authors:  E Coll; A Botey; L Alvarez; E Poch; L Quintó; A Saurina; M Vera; C Piera; A Darnell
Journal:  Am J Kidney Dis       Date:  2000-07       Impact factor: 8.860

5.  Cystatin C and the risk of death and cardiovascular events among elderly persons.

Authors:  Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

6.  Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells.

Authors:  B R Brehm; D Bertsch; J von Fallois; S C Wolf
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

7.  Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.

Authors:  James L Januzzi; Steven M Snapinn; Peter M DiBattiste; Ik-Kyung Jang; Pierre Theroux
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

8.  Depressive symptoms and health-related quality of life: the Heart and Soul Study.

Authors:  Bernice Ruo; John S Rumsfeld; Mark A Hlatky; Haiying Liu; Warren S Browner; Mary A Whooley
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

Review 9.  Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence.

Authors:  Robert S Rosenson; Alan S Brown
Journal:  Curr Opin Lipidol       Date:  2002-12       Impact factor: 4.776

10.  Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.

Authors:  Jassim Al Suwaidi; Donal N Reddan; Kathryn Williams; Karen S Pieper; Robert A Harrington; Robert M Califf; Christopher B Granger; E Magnus Ohman; David R Holmes
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  10 in total

1.  Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty.

Authors:  Michal Droppa; Steffen Desch; Patrick Blase; Ingo Eitel; Georg Fuernau; Gerhard Schuler; Volker Adams; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2011-06-28       Impact factor: 5.460

2.  Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease.

Authors:  Grazina Urbonaviciene; Guo Ping Shi; Sigitas Urbonavicius; Eskild W Henneberg; Jes S Lindholt
Journal:  Atherosclerosis       Date:  2011-02-18       Impact factor: 5.162

Review 3.  Association Between Cystatin C and the Risk of Ischemic Stroke: a Systematic Review and Meta-analysis.

Authors:  Yan Wang; Wei Li; Jun Yang; Mijuan Zhang; Chun'e Tian; Minjiang Ma; Qian Zhang
Journal:  J Mol Neurosci       Date:  2019-07-17       Impact factor: 3.444

4.  Association between cystatin C and heart failure with preserved ejection fraction in elderly Chinese patients.

Authors:  C C Xu; G X Fu; Q Q Liu; Y Zhong
Journal:  Z Gerontol Geriatr       Date:  2016-05-20       Impact factor: 1.281

5.  Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus.

Authors:  Asli Tanindi; Hilal Olgun; Ayse Tuncel; Bulent Celik; Hatice Pasaoglu; Bulent Boyaci
Journal:  Vasc Health Risk Manag       Date:  2011-02-06

6.  Improving the prediction of long-term readmission and mortality using a novel biomarker panel.

Authors:  Jeremiah R Brown; Devin M Parker; Meagan E Stabler; Marshall L Jacobs; Jeffrey P Jacobs; Allen D Everett; Kevin W Lobdell; Moritz C Wyler von Ballmoos; Heather Thiessen-Philbrook; Chirag Parikh; Todd Mackenzie; Anthony DiScipio; David Malenka; Michael E Matheny; Alexander Turchin; Donald S Likosky
Journal:  J Card Surg       Date:  2021-09-02       Impact factor: 1.778

7.  Clinical application of simultaneous detection of cystatin C, cathepsin S, and IL-1 in classification of coronary artery disease.

Authors:  Ling Yan; Shuang Ding; Bing Gu; Ping Ma
Journal:  J Biomed Res       Date:  2017-07-13

8.  Relationship between serum cystatin-c and coronary lesion severity in coronary artery disease patients with a normal glomerular filtration rate.

Authors:  Junqiang Pan; Xifeng Sun; Pengjie Zhang; Haichao Chen; Jing Lin
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

9.  Cystatin C: a strong marker for lower limb ischemia in Chinese type 2 diabetic patients?

Authors:  Fang Liu; Jing Shen; Jun Zhao; Hui Zeng; Lianxi Li; Jungong Zhao; Fengdi Lu; Yuqian Bao; Weiping Jia
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

10.  Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus.

Authors:  Zhenhong Fu; Hao Xue; Jun Guo; Lian Chen; Wei Dong; Luyue Gai; Hongbin Liu; Zhijun Sun; Yundai Chen
Journal:  Cardiovasc Diabetol       Date:  2013-11-01       Impact factor: 9.951

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.